Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia.
Between June 1994 and October 1995 we performed 11 autografts in nine patients with advanced-phase chronic myeloid leukaemia (CML) using an attenuated cytoreductive regimen consisting of busulphan 8 mg/kg given in divided doses over 4 d. Five patients were restored to chronic phase. Four patients survived > 50 weeks and one remains well at 79 weeks. Toxicity was generally mild. Four procedures were managed entirely in the out-patient clinic. Therefore autografting after this 'intermediate' dose busulphan provides good palliation for patients with advanced CML with relatively little toxicity. Attenuated autografting should offer major advantages in terms of quality of life and cost for patients with advanced-phase CML.
Rule
S A
SA
Department of Haematology, Royal Postgraduate Medical School, London.
Savage
D G
DG
O'Brien
S G
SG
Orchard
K
K
McDonald
C
C
Davidson
J
J
Matthey
F
F
Reilly
J T
JT
Bardhan
G
G
Miller
E
E
Cranfield
T
T
Apperley
J F
JF
Goldman
J M
JM
D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000379:methods*; D002066:Busulfan / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006760:Hospitalization; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology; D012008:Recurrence; D014182:Transplantation, Autologous
D002066:Busulfan